The EPS projection of Medtronic, Inc. (NYSE:MDT) for period quarter closed 2017-01-31 is $1.15.
The EPS estimates given 30-days and 1 week ago were $1.15 and $1.15, correspondingly. This number 90 and 60 days before was $1.15 and $1.15 respectively. Yet, from last week, the change in EPS prediction is 0%.
For the quarter ended 1 mean estimate is $1.15 based on 19 EPS estimations. As on 2016-08-25 estimated EPS was $1.03 showing surprise of $0.02, or 1.98%. Following the given predictions, the standard deviation is $0.01.
The upgrade count for EPS revisions was 0 a week earlier paralleled to negative revisions of 0. In last 60-days and 1- month, the upgrade in EPS reviews were 6 and 0 correspondingly, though for a quarter and 120-days ago, it was 6 and 6 in that sequence.
The negative reviews of EPS in the last 60-days and 1-month were 0 and 6 in that order. But, a quarter and 120-days ago, this numeral was 6 and 6 correspondingly.
EPS reviews downgrade and upgrade for last 18 days were 2 and 7, correspondingly.
Quarterly Sales Estimates
The mathematical mean of apparent yearly sales of Medtronic, Inc. (NYSE:MDT) is $9830.372 and the median is $9864.86. The estimate is stated by 5 analysts for the fiscal 2021.
The highest yearly projection is $10300.56 and lowest sales mark is $9311.39. This results a standard deviation of $357.017.
Almost 5 have reviewed sales target for better in the past week and 5 have downgraded forecasts. Subject to the stated estimates, the intended change in disclosed target from the past week is 0%.
Nearly 5 revised sales predictions for better over the past month and 5 have downgraded forecasts. It suggests an average deviation of 0% across given estimates.
Just about 5 have revised sales forecast up over the quarter and 5 have downgraded forecasts, hinting to a deviation of 0.115%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...